[go: up one dir, main page]

WO2009033808A3 - Utilisation d'un peptide en tant qu'agent thérapeutique - Google Patents

Utilisation d'un peptide en tant qu'agent thérapeutique Download PDF

Info

Publication number
WO2009033808A3
WO2009033808A3 PCT/EP2008/008136 EP2008008136W WO2009033808A3 WO 2009033808 A3 WO2009033808 A3 WO 2009033808A3 EP 2008008136 W EP2008008136 W EP 2008008136W WO 2009033808 A3 WO2009033808 A3 WO 2009033808A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
leu
peptide
therapeutic agent
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/008136
Other languages
English (en)
Other versions
WO2009033808A2 (fr
Inventor
Dorian Bevec
Fabio Cavalli
Vera Cavalli
Gerald Bacher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mondobiotech Laboratories AG
Original Assignee
Mondobiotech Laboratories AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mondobiotech Laboratories AG filed Critical Mondobiotech Laboratories AG
Publication of WO2009033808A2 publication Critical patent/WO2009033808A2/fr
Publication of WO2009033808A3 publication Critical patent/WO2009033808A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'utilisation de la combinaison de Pyr-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-lle-Leu-OH et de Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH2 en tant que combinaison thérapeutique destinée à la prophylaxie et/ou au traitement du cancer, d'une maladie cardiaque et vasculaire, d'une maladie infectieuse, d'une maladie fibreuse, d'une maladie inflammatoire, d'une maladie neurodégénérative ou d'une maladie auto-immune.
PCT/EP2008/008136 2007-09-11 2008-09-09 Utilisation d'un peptide en tant qu'agent thérapeutique Ceased WO2009033808A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07017746.4 2007-09-11
EP07017749 2007-09-11
EP07017749.8 2007-09-11
EP07017746 2007-09-11

Publications (2)

Publication Number Publication Date
WO2009033808A2 WO2009033808A2 (fr) 2009-03-19
WO2009033808A3 true WO2009033808A3 (fr) 2009-08-20

Family

ID=40452592

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/008136 Ceased WO2009033808A2 (fr) 2007-09-11 2008-09-09 Utilisation d'un peptide en tant qu'agent thérapeutique

Country Status (1)

Country Link
WO (1) WO2009033808A2 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929756A (en) * 1973-11-21 1975-12-30 Univ Brandeis Synthetically produced tridecapeptide having the same activity as the hypothalamic substance, neurotensin
JPS59175460A (ja) * 1983-03-24 1984-10-04 Ajinomoto Co Inc デカペプチド
EP0892053A2 (fr) * 1997-07-14 1999-01-20 Smithkline Beecham Plc Production de polypeptide HPMBQ91 recombinant et ses utilisations
EP1157695A1 (fr) * 2000-04-27 2001-11-28 Pfizer Products Inc. Méthode pour traiter l'obésité avec un ligand du récepteur de la neurotensine
US20040014651A1 (en) * 2002-07-18 2004-01-22 Elliott Richelson Treating the effects of nicotine
US20050119454A1 (en) * 2000-01-24 2005-06-02 The Cielo Institute, Inc. Algorithmic design of peptides for binding and/or modulation of the functions of receptors and/or other proteins
US20060281670A1 (en) * 2005-06-10 2006-12-14 Wisconsin Alumni Research Foundation (Warf) Compositions and methods for modulating angiogenesis

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929756A (en) * 1973-11-21 1975-12-30 Univ Brandeis Synthetically produced tridecapeptide having the same activity as the hypothalamic substance, neurotensin
JPS59175460A (ja) * 1983-03-24 1984-10-04 Ajinomoto Co Inc デカペプチド
EP0892053A2 (fr) * 1997-07-14 1999-01-20 Smithkline Beecham Plc Production de polypeptide HPMBQ91 recombinant et ses utilisations
US20050119454A1 (en) * 2000-01-24 2005-06-02 The Cielo Institute, Inc. Algorithmic design of peptides for binding and/or modulation of the functions of receptors and/or other proteins
EP1157695A1 (fr) * 2000-04-27 2001-11-28 Pfizer Products Inc. Méthode pour traiter l'obésité avec un ligand du récepteur de la neurotensine
US20040014651A1 (en) * 2002-07-18 2004-01-22 Elliott Richelson Treating the effects of nicotine
US20060281670A1 (en) * 2005-06-10 2006-12-14 Wisconsin Alumni Research Foundation (Warf) Compositions and methods for modulating angiogenesis

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANIL K MANTHA ET AL: "Membrane Associated Functions of Neurokinin B (NKB) on A[beta] (25-35) Induced Toxicity in Aging Rat Brain Synaptosomes", BIOGERONTOLOGY, KLUWER ACADEMIC PUBLISHERS, DO, vol. 7, no. 1, 1 February 2006 (2006-02-01), pages 19 - 33, XP019230599, ISSN: 1573-6768 *
ANIL K MANTHA ET AL: "Neuroprotective Role of Neurokinin B (NKB) on [beta]-amyloid (25-35) Induced Toxicity in Aging Rat Brain Synaptosomes: Involvement in Oxidative Stress and Excitotoxicity", BIOGERONTOLOGY, KLUWER ACADEMIC PUBLISHERS, DO, vol. 7, no. 1, 1 February 2006 (2006-02-01), pages 1 - 17, XP019230598, ISSN: 1573-6768 *
EISUKE ET AL: "Neurokinin A and B", COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY. C. COMPARATIVEPHARMACOLOGY, PERGAMON PRESS , OXFORD, GB, vol. 98, no. 1, 1 January 1991 (1991-01-01), pages 171 - 179, XP025945404, ISSN: 0306-4492, [retrieved on 19910101] *
KATSANOS G S ET AL: "Biology of neurotensin: Revisited study", INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, vol. 21, no. 2, April 2008 (2008-04-01), pages 255 - 259, XP009118435, ISSN: 0394-6320 *
SEVERINI C ET AL: "The Tachykinin Peptide Family", PHARMACOLOGICAL REVIEWS, WILLIAMS AND WILKINS INC., BALTIMORE, MD, US, vol. 54, no. 2, 1 January 2002 (2002-01-01), pages 285 - 322, XP002981022, ISSN: 0031-6997 *
ST-GELAIS FANNIE ET AL: "The role of neurotensin in central nervous system pathophysiology: What is the evidence?", JOURNAL OF PSYCHIATRY & NEUROSCIENCE, vol. 31, no. 4, July 2006 (2006-07-01), pages 229 - 245, XP009118431, ISSN: 1180-4882 *
YANG ET AL: "Bimodal effects of chronically administered neurokinin B (NKB) on in vivo and in vitro cardiovascular responses in female rats", REGULATORY PEPTIDES, ELSEVIER SCIENCE BV, NL, vol. 143, no. 1-3, 10 August 2007 (2007-08-10), pages 136 - 142, XP022192151, ISSN: 0167-0115 *

Also Published As

Publication number Publication date
WO2009033808A2 (fr) 2009-03-19

Similar Documents

Publication Publication Date Title
WO2009033821A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009043518A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009043522A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
LTPA2017015I1 (lt) Apoptozę sukeliantys agentai, skirti vėžio ir imuninių ir autoimuninių ligų gydymui
EA201201400A1 (ru) Композиции и способы лечения аутоиммунных и других заболеваний
HUE050998T2 (hu) Gyógyszerek fibrotikus betegségek kezelésére
WO2007135026A3 (fr) Ptéridines substituées
WO2009033819A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2012061390A3 (fr) Compositions et procédés thérapeutiques
WO2010094734A3 (fr) Procédés d'identification de composés utiles pour le diagnostic et le traitement de maladies liées à une inflammation
WO2010088527A3 (fr) Peptides et nanoparticules pour des applications thérapeutiques et diagnostiques
WO2009103959A3 (fr) Médicament
WO2009033813A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009043525A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033818A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009046875A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033814A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009046872A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033820A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033816A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033809A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2008051421A3 (fr) Composés cytotoxiques de peptides
WO2009043519A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033812A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2008009426A9 (fr) Dérivés de 5-cyano-prostacycline utilisés comme agents dans le traitement de maladies auto-immunes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08802605

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 203867

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08802605

Country of ref document: EP

Kind code of ref document: A2